Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma - PubMed (original) (raw)
Review
Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma
Lauren C Harshman et al. Cancer J. 2013 Jul-Aug.
Abstract
The product of a proto-oncogene, the c-Met protein is a transmembrane receptor tyrosine kinase. Its only known ligand, hepatocyte growth factor/scatter factor, regulates cell growth, motility, migration, invasion, proliferation, and angiogenesis. Dysregulation of c-Met and hepatocyte growth factor have been observed in both clear cell and non-clear cell renal cell carcinomas (RCCs), although only papillary RCCs harbor activating mutations in the MET gene. In clear cell RCC, there is evidence of a direct link between loss of von Hippel-Lindau and up-regulation of c-Met. As in other cancers, high expression of c-Met correlates with worse outcomes in RCC. In vitro and in vivo preclinical RCC models demonstrate cancer control with small molecule and antibodies against c-Met. Given these findings, the c-Met pathway is a logical therapeutic target in RCC, and several agents are in clinical testing with early signs of efficacy.
Similar articles
- Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma.
Morris MR, Gentle D, Abdulrahman M, Maina EN, Gupta K, Banks RE, Wiesener MS, Kishida T, Yao M, Teh B, Latif F, Maher ER. Morris MR, et al. Cancer Res. 2005 Jun 1;65(11):4598-606. doi: 10.1158/0008-5472.CAN-04-3371. Cancer Res. 2005. PMID: 15930277 - The prospect of precision therapy for renal cell carcinoma.
Ciccarese C, Brunelli M, Montironi R, Fiorentino M, Iacovelli R, Heng D, Tortora G, Massari F. Ciccarese C, et al. Cancer Treat Rev. 2016 Sep;49:37-44. doi: 10.1016/j.ctrv.2016.07.003. Epub 2016 Jul 12. Cancer Treat Rev. 2016. PMID: 27453294 Review. - Non-clear cell advanced kidney cancer: is there a gold standard?
Sánchez P, Calvo E, Durán I. Sánchez P, et al. Anticancer Drugs. 2011 Jan;22 Suppl 1:S9-14. doi: 10.1097/01.cad.0000390767.85658.83. Anticancer Drugs. 2011. PMID: 21173605 Review. - Germline and somatic c-met mutations in multifocal/bilateral and sporadic papillary renal carcinomas of selected patients.
Salvi A, Marchina E, Benetti A, Grigolato P, De Petro G, Barlati S. Salvi A, et al. Int J Oncol. 2008 Aug;33(2):271-6. Int J Oncol. 2008. PMID: 18636147 - A novel recombinant soluble splice variant of Met is a potent antagonist of the hepatocyte growth factor/scatter factor-Met pathway.
Tiran Z, Oren A, Hermesh C, Rotman G, Levine Z, Amitai H, Handelsman T, Beiman M, Chen A, Landesman-Milo D, Dassa L, Peres Y, Koifman C, Glezer S, Vidal-Finkelstein R, Bahat K, Pergam T, Israel C, Horev J, Tsarfaty I, Ayalon-Soffer M. Tiran Z, et al. Clin Cancer Res. 2008 Jul 15;14(14):4612-21. doi: 10.1158/1078-0432.CCR-08-0108. Clin Cancer Res. 2008. PMID: 18628476
Cited by
- Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy.
Grassi P, Verzoni E, Ratta R, Mennitto A, de Braud F, Procopio G. Grassi P, et al. Drug Des Devel Ther. 2016 Jul 5;10:2167-72. doi: 10.2147/DDDT.S104225. eCollection 2016. Drug Des Devel Ther. 2016. PMID: 27462141 Free PMC article. Review. - Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET.
Rankin EB, Fuh KC, Castellini L, Viswanathan K, Finger EC, Diep AN, LaGory EL, Kariolis MS, Chan A, Lindgren D, Axelson H, Miao YR, Krieg AJ, Giaccia AJ. Rankin EB, et al. Proc Natl Acad Sci U S A. 2014 Sep 16;111(37):13373-8. doi: 10.1073/pnas.1404848111. Epub 2014 Sep 3. Proc Natl Acad Sci U S A. 2014. PMID: 25187556 Free PMC article. - Design and characterization of the tumor vaccine MGN1601, allogeneic fourfold gene-modified vaccine cells combined with a TLR-9 agonist.
Volz B, Schmidt M, Heinrich K, Kapp K, Schroff M, Wittig B. Volz B, et al. Mol Ther Oncolytics. 2016 Feb 10;3:15023. doi: 10.1038/mto.2015.23. eCollection 2016. Mol Ther Oncolytics. 2016. PMID: 27119114 Free PMC article. - Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.
Zhou L, Liu XD, Sun M, Zhang X, German P, Bai S, Ding Z, Tannir N, Wood CG, Matin SF, Karam JA, Tamboli P, Sircar K, Rao P, Rankin EB, Laird DA, Hoang AG, Walker CL, Giaccia AJ, Jonasch E. Zhou L, et al. Oncogene. 2016 May;35(21):2687-97. doi: 10.1038/onc.2015.343. Epub 2015 Sep 14. Oncogene. 2016. PMID: 26364599 Free PMC article. - Landmarks in the diagnosis and treatment of renal cell carcinoma.
Bhatt JR, Finelli A. Bhatt JR, et al. Nat Rev Urol. 2014 Sep;11(9):517-25. doi: 10.1038/nrurol.2014.194. Epub 2014 Aug 12. Nat Rev Urol. 2014. PMID: 25112856 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous